My Profile

Search abstracts

Lewis Sheiner

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

Křbenhavn, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

Friday June 25
09:00-09:45 Registration
09:45-10:00 Welcome
Oral session I Software chair: A. Thomson
10:00-10:15 C. Pobel NONMEM running on a PC workstation: installation and use in a Clinical Pharmacy Department
10:15-10:30  P. Girard, A. Laffont, J.P. Boissel Interface between NONMEM output and an Exploratory Data Analysis Tool
10:30-10:45 D. Stephens The POPKAN Software
10:45-11:00 R. Gomeni P-Pharm : A Population Pharmacokinetic-Pharmacodynamic Data Modeling Program
11:00-11:30 Coffee break
Oral session II Comparison of methodologies chair: W. Weber
11:30-12:00 J. Wakefield Comparison of approaches - Population Pharmacokinetics of Quinidine
12:00-12:15 N. Best, W. Gilks, K. Tan Population Pharmacokinetic Modelling using the GIBBS Sampler
12:15-12:30 M.C. Iliadis, R. Bruno, V. Cosson, J.C. Vergniol, A. Mallet, G. Montay, D. Oulid-Aissa, M. Marty, M. Clavel, M. Aapro, A. Frydman, M. Bayssas, A. Iliadis Taxotere Population Pharmacokinetics during Phase I Studies : Comparison of NONMEM and NPML
12:30-12:45 E. Fuseau, S. Lettis, L. Lacey Simulated Population Pharmacokinetic Data for Use in Assessing the Robustness of Current Population Methods
12:45-14:00 Lunch
Oral session III chair: J. Van Bree
14:00-14:15 L. Aarons The use of an EM algorithm for parameter estimation from spare data
14:15-14:30 F.Y. Bois, D. Maszle, A. Gelman A Toxicokinetic Analysis of Tetra Chloroethylene Methabolism in Humans
14:30-14:45 L.S. Murray, S. Senan, J. Cassidy, P. Workman, S.B. Kaye, M.A. Graham A Preliminary report on the Pharmacokinetics of Tirapazamine
14:45-15:00 C. Laveille, M. Chic, F. Dubois, R. Jochemsen Indapamide population pharmacokinetics via mixed effects modeling: models building and bayesian estimation of pharmacokinetics parameters
15:00-15:15 W. Weber, L. Harnisch Population pharmacokinetics in paediatric patients : comparison of empirical renal clearance models
15:15-15:30 A. Laffont, P. Girard, P. Maire, X. Barbaut, G. Chapelle, C. Pobel, T. Berod, C. Pivot, B. Lacarelle, J. Debord, R.W. Jelliffe, J.P. Boissel Multicenter study of Amikacyn Pharmacokinetics from patients under TDM
15:30-15:45 N. Taright, F. Mentré, R. Jouvent, S. Ammar, A Mallet Population analysis of the kinetics of litium using NPML and evaluation of the estimated characteristics on a group of patients regimen
15:45-16:30 Tea break
Tutorial chair: S. Vozeh
16:30-17:30 F. Mentré Optimal Design in Population Analysis Including Bayesian Aspects
Oral session IV Population approach in Drug Development chair: S. Vozeh
17:30-17:45 J.L. Steimer Points to consider when presenting population analysis to regulatory autorities
17:45-18:00 A. Van Peer International Harmonisation of Guidelines on Studies in Special Patient Populations
18:80-18:15 R. Bruno, T. Joumard, N. Vivier, J.C. Vergniol, V. Cosson, G. Montay, F. This, M. Bayssas, A. Frydman Implementation of Population Pharmacokinetic Studies during Drug Development : Success Factors
18:15-18:30 PAGE prospects : general discussion (R. Bruno, P. Girard, J.L. Steimer, B. Tranchand)
COST B1 - Next meeting(s) ? - Organizing Committee
18:30 End of the meeting